SLC5A2 and diabetes mellitus: There were no significant discrepancies between the efficacy of GLP-1 agonists and SGLT-2 inhibitors for reducing MAGE among patients with diabetes (SMD = −0.59, 95% CI = −0.82 to −0.36 vs. SMD = −0.43, 95% CI = −0.51 to −0.35, respectively; Figure 2a).